Using Antibody-Drug Conjugates to Selectively Inhibit Disease-Driving TGF-β Isoforms & Cells
Time: 1:30 pm
day: Conference Day Two
Details:
- Introduce a novel therapeutic approach to target the TGF-β pathway, a key driver of fibrosis, while improving efficacy, safety, and patient outcomes through selective inhibition
- Discuss the design and development of cell-targeted ADCs that inhibit TGF-β in pathogenic cell populations, enhancing on-target specificity and minimizing off-target effects compared to systemic therapies
- Explore the utility of ADC-based strategies for organ-specific fibrotic diseases, leveraging fibrosis-associated surface markers to guide targeted delivery and broaden therapeutic potential
